Clik here to view.
Scientists unveil new way to make large changes to genes, and no CRISPR is...
Scientists led by Patrick Hsu at the Arc Institute in Palo Alto have unveiled a new form of gene editing that can add, remove or flip large stretches of DNA — all without the help of CRISPR. CRISPR...
View ArticleClik here to view.
Optum Rx may enter biosimilar market to match competitors CVS, Express Scripts
Top PBM Optum Rx may be moving into the biosimilar business, joining its competitors CVS and Express Scripts, according to a US trademark application for a business called Nuvaila. The application to...
View ArticleHaleon to sell nicotine replacement therapy business to Dr. Reddy’s for $630M
Haleon has agreed to sell its ex-US nicotine replacement therapy business to Dr. Reddy’s for a total of £500 million, or about $630 million, the company announced Wednesday. Under the deal, Haleon will...
View ArticleClik here to view.
Updated: CDC expands RSV vaccine recommendations, namely for adults 75 and older
The CDC advisory panel that helps set US vaccine policy said the use of RSV shots should be expanded to more adults, recommending the shot for all people 75 and older and for those aged 60 to 74 at...
View ArticleFDA approves new COPD drug from Verona Pharma
The FDA approved Verona Pharma’s drug for chronic obstructive pulmonary disease, or COPD, the first maintenance treatment with a new mechanism for the ailment in over two decades, according to the...
View ArticleClik here to view.
Digital health funding flattens out, PitchBook report shows
(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) Despite a number of high-profile late-stage megarounds, overall funding for startups seems to have...
View ArticleFDA rejects Daiichi's HER3 ADC, a blow to quick approval plans for Merck...
The FDA has given a thumbs down to Daiichi Sankyo’s HER3 antibody-drug conjugate patritumab deruxtecan. The Wednesday rejection deals a blow to the Japanese pharma’s plans for a near-term expansion of...
View ArticleAbbVie and Genmab score accelerated follicular lymphoma nod for Epkinly
AbbVie and Genmab are celebrating their second accelerated approval for Epkinly, this time in follicular lymphoma. The bispecific antibody, also known as epcoritamab, was approved on Wednesday for...
View ArticleEuroAPI overhaul comes into focus with plans to cut 550 staffers and divest...
Sanofi spin-off EuroAPI provided further details on its restructuring plan, with the company cutting 550 staffers and divesting two facilities — one in Brindisi, Italy, and the other in Haverhill, UK....
View ArticleClik here to view.
Maze spins its ALS antisense program into a secretive new company
Maze Therapeutics is putting one of its neuroscience programs into a new stealth company, months after having its partnership deal with Sanofi blocked by the FTC. The biotech’s plans were quietly...
View ArticleLongevity investors look to add $200M to the table with new growth fund
Bold Capital Partners, a life sciences and deep tech investor, is raising a new fund to support biotechs and diagnostics makers focused on “healthy human life extension.” The so-called BOLD Longevity...
View ArticleMIT scientists launch spatial biology startup to test hundreds of cell...
Therapies made from a patient’s own immune cells have spurred medical miracles for many people with advanced blood cancers, but getting those CAR-T cell therapies to work more broadly in solid tumors...
View ArticleOne Medical CEO-turned-VC wants startups that are 'disruptive from within the...
Amir Dan Rubin has had the success many healthcare executives dream about. The former CEO of One Medical grew the primary care chain to hundreds of locations and sold it last year to Amazon for $3.9...
View ArticleQ&A: Vertex’s pain research chief on moving beyond opioids, AI and how pharma...
SAN DIEGO — For savvy dealmaking, Vertex’s 2001 acquisition of Aurora Biosciences is near the top of the list. Vertex bought the San Diego biotech for $592 million in stock. The site eventually...
View ArticleSilence reports Phase 1 data from rare blood disorder trial
Silence Therapeutics touted Phase 1 data from an ongoing study Thursday morning in patients with a rare disease where their bone marrow produces too many red blood cells. The results, which come from a...
View ArticleClik here to view.
AbbVie buys Third Rock's Celsius for $250M to expand IBD pipeline
As AbbVie continues to tout its next generation of immunology drugs behind Humira, it’s buying an early-stage startup to boost its longer-term prospects in inflammatory bowel disease. The Chicago-area...
View ArticleRecursion’s $200M offering; Sanofi invests $40M in Vigil Neuroscience
Plus, news about 2seventy, Novo Nordisk, CASI, CalciMedica, X4, NeOnc, ANI, Alimera, Holoclara, Nxera, Future Pak, Vanda and Bayer: Recursion Pharmaceuticals is selling $200M in shares: The company is...
View ArticleClik here to view.
Biogen is pursuing more dealmaking this year, with plans to spend up to $8B
Biogen appears to be subtly signaling it has a larger appetite for M&A than previously stated. In an exclusive interview with Endpoints News, Biogen head of corporate development Adam Keeney said...
View ArticleSK Bioscience takes majority stake in CDMO for $244M; Ex-Lonza CEO joins Cytiva
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. SK Bioscience now has a 60% stake in the CDMO IDT Biologika after...
View ArticleGSK’s manufacturing sites in Singapore will use 100% renewable energy by 2025
GSK said it is on track to convert its global manufacturing sites into using renewable electricity, with its facilities in Singapore becoming the latest to make the transition. The UK pharma has signed...
View Article